TY - JOUR
T1 - An international survey of classification and treatment choices for group D retinoblastoma
AU - Scelfo, Christina
AU - Francis, Jasmine H.
AU - Khetan, Vikas
AU - Jenkins, Thomas
AU - Marr, Brian
AU - Abramson, David H.
AU - Shields, Carol L.
AU - Pe’er, Jacob
AU - Munier, Francis
AU - Berry, Jesse
AU - Harbour, J. William
AU - Yarovoy, Andrey
AU - Lucena, Evandro
AU - Murray, Timothy G.
AU - Bhagia, Pooja
AU - Paysse, Evelyn
AU - Tuncer, Samuray
AU - Chantada, Guillermo L.
AU - Moll, Annette C.
AU - Ushakova, Tatiana
AU - Plager, David A.
AU - Ziyovuddin, Islamov
AU - Leal, Carlos A.
AU - Materin, Miguel A.
AU - Ji, Xun Da
AU - Cursino, Jose W.
AU - Polania, Rodrigo
AU - Kiratli, Hayyam
AU - All-Ericsson, Charlotta
AU - Kebudi, Rejin
AU - Honavar, Santosh G.
AU - Vishnevskia-Dai, Vicktoria
AU - Epelman, Sidnel
AU - Daniels, Anthony B.
AU - Ling, Jeanie D.
AU - Traore, Fousseyni
AU - Ramirez-Ortiz, Marco A.
PY - 2017/6/18
Y1 - 2017/6/18
N2 - • AIM: To determine which IIRC scheme was used by retinoblastoma centers worldwide and the percentage of D eyes treated primarily with enucleation versus globe salvaging therapies as well as to correlate trends in treatment choice to IIRC version used and geographic region. • METHODS: An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about IIRC classification schemes and treatment patterns used between 2008 and 2012. Participants were asked to record which version of the IIRC was used for classification, how many group D eyes were diagnosed, and how many eyes were treated with enucleation versus globe salvaging therapies. Averages of eyes per treatment modality were calculated and stratified by both IIRC version and geographic region. Statistical significance was determined by Chi-square, ANOVA and Kruskal-Wallis tests using Prism. • RESULTS: The survey was completed by 29% of physicians invited to participate. Totally 1807 D eyes were diagnosed. Regarding IIRC system, 27% of centers used the Childrenfs Hospital of Los Angeles (CHLA) version, 33% used the Childrenfs Oncology Group (COG) version, 23% used the Philadelphia version, and 17% were unsure. The rate for primary enucleation varied between 0 and 100% and the mean was 29%. By IIRC version, primary enucleation rates were: Philadelphia, 8%; COG, 34%; and CHLA, 37%. By geographic region, primary enucleation rates were: Latin America, 57%; Asia, 40%; Europe, 36%; Africa, 10%, US, 8%; and Middle East, 8%. However, systemic chemoreduction was used more often than enucleation in all regions except Latin America with a mean of 57% per center (P<0.0001). • CONCLUSION: Worldwide there is no consensus on which IIRC version is used, systemic chemoreduction was the most frequently used initial treatment during the study period followed by enucleation and primary treatment modality, especially enucleation, varied greatly with regards to IIRC version used and geographic region.
AB - • AIM: To determine which IIRC scheme was used by retinoblastoma centers worldwide and the percentage of D eyes treated primarily with enucleation versus globe salvaging therapies as well as to correlate trends in treatment choice to IIRC version used and geographic region. • METHODS: An anonymized electronic survey was offered to 115 physicians at 39 retinoblastoma centers worldwide asking about IIRC classification schemes and treatment patterns used between 2008 and 2012. Participants were asked to record which version of the IIRC was used for classification, how many group D eyes were diagnosed, and how many eyes were treated with enucleation versus globe salvaging therapies. Averages of eyes per treatment modality were calculated and stratified by both IIRC version and geographic region. Statistical significance was determined by Chi-square, ANOVA and Kruskal-Wallis tests using Prism. • RESULTS: The survey was completed by 29% of physicians invited to participate. Totally 1807 D eyes were diagnosed. Regarding IIRC system, 27% of centers used the Childrenfs Hospital of Los Angeles (CHLA) version, 33% used the Childrenfs Oncology Group (COG) version, 23% used the Philadelphia version, and 17% were unsure. The rate for primary enucleation varied between 0 and 100% and the mean was 29%. By IIRC version, primary enucleation rates were: Philadelphia, 8%; COG, 34%; and CHLA, 37%. By geographic region, primary enucleation rates were: Latin America, 57%; Asia, 40%; Europe, 36%; Africa, 10%, US, 8%; and Middle East, 8%. However, systemic chemoreduction was used more often than enucleation in all regions except Latin America with a mean of 57% per center (P<0.0001). • CONCLUSION: Worldwide there is no consensus on which IIRC version is used, systemic chemoreduction was the most frequently used initial treatment during the study period followed by enucleation and primary treatment modality, especially enucleation, varied greatly with regards to IIRC version used and geographic region.
KW - Cancer
KW - Chemotherapy
KW - Enucleation
KW - Intra-arterial chemotherapy
KW - Oncology
KW - Ophthalmic artery chemosurgery
KW - Retina
KW - Retinoblastoma
UR - http://www.scopus.com/inward/record.url?scp=85020910381&partnerID=8YFLogxK
U2 - https://doi.org/10.18240/ijo.2017.06.20
DO - https://doi.org/10.18240/ijo.2017.06.20
M3 - Article
C2 - 28730089
SN - 2222-3959
VL - 10
SP - 961
EP - 967
JO - INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
JF - INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
IS - 6
ER -